Zymo Research Launches Quick-cfRNA™ Serum & Plasma Kit Ideal for RT-qPCR, Next Generation Sequencing and Liquid Biopsy Research

VANCOUVER, British Columbia, Oct. 18, 2016 PRNewswire -- Zymo Research Corporation will launch its Quick-cfRNA™Serum & Plasma Kit, which is currently in beta test, at ASHG 2016, Booth #112. Genetic researchers who need a reliable and robust method to purify cell-free RNA (cfRNA) from up to 1 ml of plasma, serum, or other biological fluids can use the Quick-cfRNA™ Serum & Plasma Kit. Isolated RNA is immediately ready for sensitive downstream applications including RT-qPCR and Next Generation Sequencing. The kit enables simple, reliable, and efficient preparation of high-quality circulating cell-free RNA (including protein-bound, exosomal, miRNA and other small RNAs) from serum, plasma, amniotic fluid, cerebrospinal fluid, saliva, and other biological fluids. Cell-free RNA naturally occurs in blood and has clinical significance. It is becoming a promising tool for non-invasive and cost effective detection of cancer and other diseases.

In addition to the new Quick-cfRNA Serum & Plasma Kit, Zymo Research will also be showing its Quick-cfDNA™ Serum & Plasma Kit. Investigators are finding that increased rates of circulating cell-free DNA (cfDNA) from tumors can be used as a biomarker source for early cancer diagnosis, prognosis, and monitoring of cancer therapy. Zymo Research's Quick-cfDNA™ Serum & Plasma Kit can be used for biomarker discovery and advanced liquid biopsy research. Liquid biopsies typically screen for free-floating pieces of DNA or RNA from cancerous cells found in the bloodstream. Researchers will capture a biological sample, such as blood or serum for disease analysis, and use that sample for a range of research applications such as RT-PCR, digital PCR, and Next Generation Sequencing. Translational genomic research is utilizing cfDNA to monitor personalized therapies based on specific tumor profiles. For these applications it is critical to recover total DNA. Zymo's Quick-cfDNA™ Serum & Plasma Kit uses a combination of chemical and enzymatic methods to efficiently recover total DNA (including cell-free apoptotic, necrotic, mitochondrial and viral DNA) linearly from up to 10 ml of sample.

Zymo Research's Zymo-Spin™ technology is featured in both kits. Its unique spin-column design allows for ultra-pure DNA or RNA to be eluted in as little as 35 μl of water. The resulting DNA or RNA is suitable for all subsequent analyses and molecular manipulations, such as qPCR, Next Generation Sequencing, and DNA methylation analyses.

About Zymo Research Corp.
Zymo Research Corp., also known as "The Epigenetics Company", is a privately held company based in Irvine, California, US. Since its inception in 1994, it has been serving the academic and biopharmaceutical scientific communities by providing DNA and RNA purification products. Zymo Research was an early adopter in the field of epigenetics and offers a line of products used in DNA methylation detection and quantitation. In addition to the epigenetic and nucleic acid purification products, Zymo also provides genetic, epigenetic and transcriptome analysis services. For more information, please visit www.zymoresearch.com/epigenetics. Follow Zymo Research Corp. on Facebook , LinkedIn, Twitter, and Instagram.

Trademarks:
All trademarks are the property of their respective owners. Zymo Research Corporation, the stylized logo, tagline "The Beauty of Science is to Make Things Simple", Quick-cfDNA, Quick-cfRNA, and Zymo-Spin are trademarks of Zymo Research Corporation and are registered with the USPTO.

October 18, 2016 | Press Releases

Your Cart